Peptide-derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to cell surface heparan sulfate

Antiviral Research

Volumn 85, Issue 3, 2010, Pages 532-540

  Luganini, Anna ^a   Giuliani, Andrea ^b   Pirri, Giovanna ^b   Pizzuto, Lorena ^b   Landolfo, Santo ^a   Gribaudo, Giorgio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Spider Biotech Srl   (Italy)

Author keywords

Antivirals; GCV resistant strains; Heparan sulfate; Human cytomegalovirus; In vitro infection; Inhibition of viral attachment; Peptide derivatized dendrimers

Indexed keywords

ANTIVIRUS AGENT; DENDRIMER; FUNCTIONAL GROUP; HEPARAN SULFATE; PEPTIDE DERIVATIVE; SB 104; SB 105; SB 105 A10; UNCLASSIFIED DRUG;

ADENOVIRUS; AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN 3T3; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DERIVATIZATION; DRUG SCREENING; DRUG STRUCTURE; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; TARGET CELL; VESICULAR STOMATITIS VIRUS; VIRUS ATTACHMENT; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELLS, CULTURED; CYTOMEGALOVIRUS; DENDRIMERS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FIBROBLASTS; HEPARITIN SULFATE; HERPESVIRIDAE INFECTIONS; HUMANS; MICE; MUROMEGALOVIRUS; PEPTIDES; RHABDOVIRIDAE INFECTIONS; VESICULOVIRUS; VIRUS ATTACHMENT; VIRUS REPLICATION;

ADENOVIRIDAE; HUMAN HERPESVIRUS 5; MURINAE; VESICULAR STOMATITIS VIRUS;

EID: 76949084904     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.01.003     Document Type: Article

References (31)

1. Azad R.F., Driver V.B., Tanaka K., Crooke R.M., and Anderson K.P. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob. Agents Chemother. 37 (1993) 1945-1954
2. Baldanti F., Michel D., Simoncini L., Heuschmid M., Zimmermann A., Minisini R., Schaarschmidt P., Schmid T., Gerna G., and Mertens T. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antiviral Res. 54 (2002) 59-67
3. Bernstein D.I., Stanberry L.R., Sacks S., Ayisi N.K., Gong Y.H., Ireland J., Mumper R.J., Holan G., Matthews B., McCarthy T., and Bourne N. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob. Agents Chemother. 47 (2003) 3784-3788
4. Bourne N., Stanberry L.R., Kern E.R., Holan G., Matthews B., and Bernstein D.I. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob. Agents Chemother. 44 (2000) 2471-2474
5. Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr. Top. Microbiol. Immunol. 325 (2008) 417-470
6. Caposio P., Musso T., Luganini A., Inoue H., Gariglio M., Landolfo S., and Gribaudo G. Targeting the NF-κB pathway through pharmacological inhibition of IKK2 prevents human cytomegalovirus replication and virus-induced inflammatory response in infected endothelial cells. Antiviral Res. 73 (2007) 175-184
7. Caposio P., Luganini A., Hahn G., Landolfo S., and Gribaudo G. Activation of the virus-induced IKK/NF-κB signaling axis is critical for the replication of human cytomegalovirus in quiescent cells. Cell. Microbiol. 9 (2007) 2040-2054
8. Cloninger M.J. Biological applications of dendrimers. Curr. Opin. Chem. Biol. 6 (2002) 742-748
9. Compton T., Nowlin D.M., and Cooper N.R. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 193 (1993) 834-841
10. De Clercq E. Emerging antiviral drugs. Expert Opin. Emerg. Drugs 13 (2008) 393-416
11. Gerna G., Percivalle E., Baldanti F., Sarasini A., Zavattoni M., Furione M., Torsellini M., and Revello M.G. Diagnostic significance and clinical impact of quantitative assays for diagnosis of human cytomegalovirus infection/disease in immunocompromised patients. New Microbiol. 21 (1998) 293-308
12. Gong E., Matthews B., McCarthy T., Chu J., Holan G., Raff J., and Sacks S. Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses. Antiviral Res. 68 (2005) 139-146
13. Greco A., Diaz J.-J., Thouvenot D., and Morfin F. Novel targets for the development of anti-herpes compounds. Infect. Disord. Drug Targets 7 (2007) 11-18
14. Heegaard P.M., and Boas U. Dendrimer based anti-infective and anti-inflammatory drugs. Rec. Pat. Anti-Infect. Drug Discov. 1 (2006) 331-351
15. Isaacson M.K., Juckem L.K., and Compton T. Virus entry and innate immune activation. Curr. Top. Microbiol. Immunol. 325 (2008) 85-100
16. Landolfo S., Gariglio M., Gribaudo G., and Lembo D. The human cytomegalovirus. Pharmacol. Ther. 98 (2003) 269-297
17. Luganini A., Caposio P., Landolfo S., and Gribaudo G. Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry. Antimicrob. Agents Chemother. 52 (2008) 1111-1120
18. Luganini A., Caposio P., Mondini M., Landolfo S., and Gribaudo G. New cell-based indicator assays for the detection of human cytomegalovirus infection and screening of inhibitors of viral immediate-early 2 protein activity. J. Appl. Microbiol. 105 (2008) 1791-1801
19. McCarthy T.D., Karellas P., Henderson S.A., Giannis M., O'Keefe D.F., Heery G., Paull J.R., Matthews B.R., and Holan G. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2 (2005) 312-318
20. Michel D., and Mertens T. Antiviral intervention, resistance and perspectives. In: Reddehase M.J. (Ed). Cytomegaloviruses. Molecular Biology and Immunology (2006), Caister Academic Press, Norfolk 573-590
21. Mocarski Jr. E.S., Shenk T., and Pass R.F. Cytomegaloviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 5th Edition (2006), Lippincott Williams & Wilkins, Philadelphia 2701-2772
22. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., and De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20 (1988) 309-321
23. Pini A., Giuliani A., Falciani C., Runci Y., Ricci C., Lelli B., Molossi M., Neri P., Rossolini G.M., and Bracci L. Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob. Agents Chemother. 49 (2005) 2665-2672
24. Pini A., Giuliani A., Falciani C., Fabbrini M., Pileri S., Lelli B., and Bracci L. Characterization of the branched antimicrobial peptide M6 by analyzing its mechanism of action and in vivo toxicity. J. Peptide Sci. 13 (2007) 393-399
25. Revello M.G., Baldanti F., Percivalle E., Saracini A., De-Giuli L., Genini E., Lilleri D., Labò N., and Gerna G. In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells. J. Gen. Virol. 82 (2001) 1429-1438
26. Rosa Borges A., and Schengrund C.L. Dendrimers and antivirals: a review. Curr. Drug Targets Infect. Disord. 5 (2005) 247-254
27. Rupp R., Rosenthal S.L., and Stanberry L.R. VivaGel™ (SPL7013 gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int. J. Nanomed. 2 (2007) 561-566
28. Sampaio K.L., Cavignac Y., Stierhof Y.D., and Sinzger C. Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements. J. Virol. 79 (2005) 2754-2767
29. Shogan B., Kruse L., Mulamba G.B., Hu A., and Coen D.M. Virucidal activity of a GT-rich oligonucleotide against herpes simplex virus mediated by glycoprotein B. J. Virol. 80 (2006) 4740-4747
30. Silvestri M.E., and Sundqvist V.A. An investigation into the heparin-binding properties of a synthetic peptide deduced from antigenic domain 2 of human cytomegalovirus glycoprotein B. Scand. J. Immunol. 53 (2001) 282-289
31. Smith I.L., Taskintuna I., Rahhal F.M., Powell H.C., Ai E., Mueller A.J., Spector S.A., and Freeman W.R. Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance. Arch. Ophthalmol. 116 (1998) 178-185